## Zydus receives final approval for Ranitidine Hcl injection

Ahmedabad, 25 February 2013

Zydus Cadila has received the final approval from the USFDA to market Ranitidine Hcl injection 25 mg/ml. Used in the treatment of <u>peptic ulcers</u>, gastritis and <u>gastroesophageal</u> reflux disease (GERD), Ranitidine Hcl falls in the anti-secretory segment.

The estimated sales in 2012 as per IMS for Ranitidine Hcl injection was USD 5.4 million.

The group now has 76 approvals and has so far filed 172 ANDAs since the commencement of the filing process in FY 2003-04.

\*\*\*